New Division of NEMA Focused on Strengthening Personalized Care for Patients

Rosslyn, VA – April 14, 2026 — The Medical Imaging and Technology Alliance (MITA) PET Group announced that it is rebranding and will now be known as the Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA). RMTA will continue the MITA PET group legacy of advancing federal policies impacting diagnostic and therapeutic radiopharmaceuticals and will expand its issue focus to include the growing field of theranostics, which are transforming how serious diseases — including cancers, heart disease, and Alzheimer’s – are detected.

RMTA, a division of the National Electrical Manufacturers Association (NEMA), unites developers of diagnostic and therapeutic radiopharmaceuticals with manufacturers of isotopes, contrast agents, nuclear imaging technologies, and integrated theranostic platforms across the healthcare industry.

“Diagnostic and therapeutic radiopharmaceuticals and theranostics are redefining precision medicine, but continued progress depends on a policy environment that keeps pace with innovation,” said Sue Bunning, executive director of RMTA. “RMTA will serve as a strong, unified voice to advance policies that expand patient access, support innovation, and reinforce American leadership in these critical technologies.”

The division will engage policymakers and stakeholders to address barriers to access, modernize regulatory and reimbursement frameworks, and advance policies that enhance safety, ensure quality, and improve patient outcomes across the care continuum.

About RMTA:

The Radiopharmaceutical Manufacturers & Theranostics Alliance (RMTA) is the leading association and collective voice for the radiopharmaceutical and contrast agent sector. Members include developers of diagnostic and therapeutic radiopharmaceuticals, as well as manufacturers of isotopes, contrast agents, nuclear imaging technologies, and integrated theranostic platforms. RMTA pursues policies that improve patient care through patient safety, product quality, and ensuring access to critical innovative diagnostics and therapies for patients suffering from cancer, heart disease, Alzheimer’s, and other chronic and non-chronic health conditions. RMTA is a division of the National Electrical Manufacturers Association (NEMA).

From: Aunt Minnie: Should coronary artery calcium (CAC) scoring be a routine part of PET/CT stress testing for assessing an individual’s risk of heart disease? Yes, according to researchers from Utah who explained why in a Saturday presentation at the American College of Cardiology (ACC) 2019 meeting in New Orleans.

From: Aunt Minnie: Researchers have developed a new FDG-PET/CT-based approach to better monitor the efficacy of immunotherapy for patients with metastatic melanoma, according to a study published in the March issue of the Journal of Nuclear Medicine. The immunotherapy treatment involves ipilimumab, a checkpoint inhibitor that allows the body’s immune system to attack cancer cells.

From: Aunt Minnie: Data from a combination of FDG-PET and functional MRI (fMRI) scans revealed the extent to which alcohol intake can alter patterns of energy use and neuronal activity in the brain, according to an article published online February 11 in Nature Communications. Researchers from the U.S. National Institutes of Health (NIH) measured glucose metabolism on brain FDG-PET scans and blood oxygenation levels on fMRI scans of 68 individuals who consumed different amounts of alcohol.

From: SNMMI: Physicians may soon have a new way to measure the efficacy or failure of hormone therapy for breast cancer patients, according to new research published in the February issue of The Journal of Nuclear Medicine. Researchers report that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been found to successfully measure changes in progesterone receptor (PR) levels resulting from a short-course estrogen treatment, also known as an estradiol challenge.